$12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza
The Access to Advanced Health Institute (AAHI) has been awarded the first stage of funding for a $12.7-million project to develop a novel immune-stimulating adjuvant formulation that will improve the human immune response to vaccines.
Registered users, subscribers or members - SIGN IN
To continue reading this article
Membership
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
Register
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
Subscribe
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.
